Colpitts, Che C.
Baumert, Thomas F.
Funding for this research was provided by:
Seventh Framework Programme (HepaMAb)
European Research Council (ERC-2014-AdG-HEPCIR)
Horizon 2020 (HEPCAR)
National Institutes of Health (1 U19 AI23862 01)
Agence Nationale de la Recherche
Canadian Institutes of Health Research (201411MFE-338606-245517)
Article History
Received: 25 October 2016
Revised: 14 November 2016
Accepted: 16 November 2016
First Online: 24 November 2016
Compliance with ethical standards
:
: The authors declare no conflict of interest. Thomas F. Baumert is a co-inventor on patent applications for claudin-1-targeting antibodies for prevention and treatment of HCV infection and liver disease.